Where is Britecyte located?

Britecyte is headquartered in Frederick, United States.

How many employees does Britecyte have?

As of Apr 30, 2026, the latest employee count at Britecyte is 8.

Is Britecyte a funded company?

Britecyte is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Britecyte rank among its competitors?

Britecyte ranks 126th amongst 222 active competitors, of which 63 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Mirum Pharmaceuticals, which secured $68.5M in Jan, 2026.

Who are the top competitors of Britecyte?

Britecyte's top competitors include argenx, Nimbus Therapeutics and Vor Biopharma. Among them, Mirum Pharmaceuticals secured the most recent funding round in January, 2026.

Britecyte - 2026 Company Profile, Team & Competitors

Company Details

Developer of regenerative medicine therapies using biocompatible cells and tissues. The company focuses on biologic therapies and tissue allografts for various medical indications. A key program involves a biologic therapy for non-alcoholic steatohepatitis (NASH), targeting metabolic pathways in NASH and adipose tissue. Additionally, it develops innovative regenerative medicine products for soft tissue repair, aiming for rapid market entry.

Key Metrics

Founded Year

2022

Location

Frederick, United States

Stage

Unfunded

Ranked

126^th among 222 active competitors

Employee Count

8 as on Apr 30, 2026

Similar Companies

argenx & 197 more

View Britecyte's full profile

Britecyte is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BRITECYTE INC CIN: 881109927 , United States, Active	Dec 31, 1999	-	5 (As on Dec 31, 2024)	-

Britecyte has not raised any funding rounds yet.

The founders of Britecyte are Peter Friedli and Alla Danilkovitch. Samson Tom is the CEO of Britecyte.

Here are the details of Britecyte's key team members:

Peter Friedli: Co-Founder & Chairman of Britecyte.
Contact Info: 1 email address
Alla Danilkovitch: Co-Founder of Britecyte.
Contact Info: 1 email address

View details of Britecyte's Founder profiles and Board Members

Britecyte's employee count trend

Britecyte has 8 employees as of Apr 26. Here is Britecyte's employee count trend over the years:

Uncover Britecyte's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Britecyte include argenx, Nimbus Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of Britecyte, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
2nd	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
3rd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
4th	Intercept Pharmaceuticals 2002, New York City (United States), Acquired	Developer of therapeutics to treat progressive non-viral liver diseases	$121M	Orbimed, JAFCO Group & 7 others	67/100
5th	Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired	Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis	$38.4M	Avoro Capital, Bay City Capital & 3 others	66/100
6th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, 8VC & 34 others	65/100
7th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Quaker Partners Management, Athyrium Capital Management ... & 4 others	64/100
8th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Deerfield & 9 others	64/100
9th	Drug Farm 2015, Shanghai (China), Series C	Developer of a novel treatment for metabolic diseases	$83M	Zhejiang Private Enterprise United Investment, BioVeda China Fund ... & 7 others	63/100
10th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
126th	Britecyte 2022, Frederick (United States), Unfunded	Developer of regenerative medicine therapies using biocompatible cells and tissues	-	-	30/100